Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Expenses (2016 - 2025)

Altimmune (ALT) has disclosed Accumulated Expenses for 16 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 40.43% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, down 40.43% year-over-year, with the annual reading at $6.1 million for FY2025, 40.43% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $6.1 million at Altimmune, down from $7.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $19.1 million in Q3 2021, with the low at $48000.0 in Q3 2022.
  • Average Accumulated Expenses over 5 years is $7.0 million, with a median of $7.6 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses plummeted 99.75% in 2022, then soared 11812.7% in 2024.
  • Over 5 years, Accumulated Expenses stood at $2.3 million in 2021, then grew by 27.76% to $3.0 million in 2022, then soared by 97.8% to $5.8 million in 2023, then skyrocketed by 75.48% to $10.3 million in 2024, then tumbled by 40.43% to $6.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $6.1 million, $7.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.